By analyzing the IMVigor210 cohort, we unexpectedly found that BLCA patients with low OBSCN expression exhibited a higher response to PD-1/PD-L1 ICIs and a better OS (Fig. 5A-B). This evidence concerns the gene OBSCN and bladder transitional cell carcinoma.